IGF Market: Competitive Landscape, Pipeline, and Market Analysis 2023

IGF is a peptide hormone that plays a crucial role in cell growth, proliferation, and differentiation. It is structurally similar to insulin and exerts its effects by binding to the IGF receptor, activating intracellular signaling pathways involved in cellular growth and metabolism. IGF is primarily used in the treatment of growth hormone deficiency (GHD) in both pediatric and adult patients. It is also utilized in certain cases of pediatric and adult short stature, muscle wasting disorders, and age-related diseases. According to WHO, growth hormone deficiency affects approximately 1 in 4,000 children worldwide. In Europe, the prevalence of GHD ranges from 1 in 3,000 to 1 in 10,000 children, with variations among countries. In the United States, an estimated 6,000 to 10,000 children have GHD. Moreover, short stature affects around 3% of children globally, with variations based on age, gender, and ethnic background. Age-related diseases, including osteoporosis and sarcopenia, are significant health concerns in the aging population. According to the European Commission, osteoporosis affects approximately 22 million women and 5.5 million men in the European Union. In the United States, over 10 million individuals have osteoporosis, and about 44 million adults aged 50 and older are affected by osteoporosis or low bone mass.

The growth drivers of the IGF market include increasing awareness of its therapeutic potential, advancements in biotechnology and genetic engineering, growing geriatric population, and favorable reimbursement policies. Companies such as Recordati, Eli Lilly, Generic mfg., Takeda, Ipsen, BMS, Viridian Therap, Oak Hill Bio, AstraZeneca, Axelar, Merck (MSD), Biogen, TriAct Therap, CSPC Pharma, Debiopharm, Silver Creek Pharma, Innovent Biologics, Kyowa Kirin, Lirum Therap, Exelixis cater to this category. Moreover, many companies are coming up with new molecules in this space. For instance, Eli Lilly is currently conducting a clinical trial of the drug IMC-A12 for the treatment of idiopathic adenocarcinoma.

Key Developments:

• In March 2023, Sandostatin LAR Depot of Novartis was registered for neuroendocrine tumors (Late-stage disease) in the European Union.
• In June 2022, Takeda launched Alunbrig for Non-small cell lung cancer (Metastatic disease) in Poland.

Approved IGF molecules

• Sandostatin LAR Depot (octreotide acetate)
• Signifor (pasireotide)
• Octreotide acetate solution for injection
• Signifor LAR (pasireotide long-acting release)
• Alunbrig (brigatinib)
• Increlex (mecasermin)
• Tepezza (teprotumumab)
• Oratrope (ibutamoren)
• Premiplex (mecasermin rinfabate)

IGF Pipeline Molecules

• Cixutumumab (IMC A12)
• Ganitumab (AMG 479)
• Linsitinib (ASP7487)
• Dalotuzumab (MK 0646)
• Figitumumab (CP-751,871)
• Xentuzumab (BI-836845)
• BMS-754807
• VRDN-001
• Dusigitumab (MEDI-573)
• Picropodophyllin (AXL1717)
• Robatumumab (SCH 717454)
• BIIB022
• EP-201
• Atesidorsen (ATL1103)
• Istiratumab (MM-141)
• IBI311
• KW-2450
• LX-101
• XL228
• Conteltinib (SY-707)
• FPI-1434
• IGV-001
• PL225B
• SAR446159
• Lonigutamab (VB421)
• Lonigutamab ugodotin (W0101)
• Masoprocol (TT-100)
• Octreotide injection (SYHX2008)
• Octreotide prolonged release (Debio 4126)
• Siroquine (JP001)

Clinical Activity and Development of IGF

In the IGF space, more than 30 companies are conducting more than 800 clinical trials in this category of drugs. For instance,

• In March 2023, H. Lee Moffitt Cancer Center and Research Institute in collaboration with Novartis and Recordati completed a phase II trial of Signifor for Neuroendocrine tumors (Metastatic disease; Inoperable/Unresectable) in the US
• In June 2021, Novartis presented long-term efficacy and adverse event data from the phase II LUNA trial in neuroendocrine carcinoma at the 57th annual meeting of the American Society of Clinical Oncology (ASCO-2021)